Table 4 |
||||||
|
Prognosis of the clusters identified in the training and validation sets |
||||||
| Cohort |
Risk cluster |
P valuea |
||||
|
|
||||||
| Total |
Low |
Medium |
High |
|||
|
|
||||||
| Training set |
||||||
| Stockholm |
n |
159 |
49 |
51 |
59 |
|
| 5-year eventb |
38 (24%) |
2 (4.2%) |
7 (14%) |
29 (49%) |
<10-7 |
|
| Treated with adjuvant therapy |
||||||
| Stockholm tamoxifen only |
Nc |
104 |
38 |
33 |
33 |
|
| 5-year event |
22 (21%) |
0 (0%) |
6 (18%) |
16 (48%) |
<10-6 |
|
| Uppsala node-positive |
n |
76 |
14 |
27 |
35 |
|
| 5-year event |
33 (43%) |
2 (14%) |
10 (37%) |
21 (60%) |
0.002 |
|
| Untreated with adjuvant therapy |
||||||
| Stockholm |
nc |
33 |
7 |
10 |
16 |
|
| 5-year event |
11 |
1 (14%) |
0 (0%) |
11 (69%) |
0.002 |
|
| Uppsala node-negative |
n |
135 |
51 |
55 |
29 |
|
| 5-year event |
17 (12%) |
3 (5.8%) |
7 (13%) |
7 (24%) |
0.02 |
|
| Van't veer |
n |
78d |
19 |
33 |
25 |
|
| 5-year event |
33 |
2 (17%) |
18 (53%) |
13 (55%) |
0.01 |
|
|
|
||||||
|
aP value for trend test. bDistant metastases or death within 5 years. cSubset of the Stockholm cohort: 82 patients with tamoxifen 2–5 years, eight patients with tamoxifen <2 years, nine patients with tamoxifen in sequence with megesterolacetat, and five patients with tamoxifen and goserelin. dOne patient was removed because of missing data. The 5-year event was distant metastases within 5 years. |
||||||
|
Pawitan et al. Breast Cancer Research 2005 7:R953 doi:10.1186/bcr1325 |
||||||
